BFRG: AI 评分 54/100 — AI 分析 (4月 2026)

BullFrog AI Holdings, Inc. is a digital biopharmaceutical company specializing in AI/ML-driven data analysis for medicine and healthcare. Their bfLEAP platform and licensing agreements target diseases like cancer and liver disease.

Key Facts: AI Score: 54/100 Sector: Healthcare

公司概况

概要：

BullFrog AI Holdings, Inc. leverages artificial intelligence and machine learning to analyze complex datasets in the healthcare sector, offering its bfLEAP platform for preclinical and clinical data analysis and pursuing therapeutic applications through licensing agreements targeting significant diseases, positioning it within the digital biopharmaceutical landscape.

BFRG是做什么的？

Founded in 2017 and based in Gaithersburg, Maryland, BullFrog AI Holdings, Inc. operates as a digital biopharmaceutical company focused on transforming healthcare through artificial intelligence and machine learning. The company's core offering is bfLEAP, a proprietary AI/ML platform designed for the analysis of preclinical and clinical data. This platform aims to accelerate drug discovery and development by identifying patterns and insights that might be missed by traditional methods. In addition to its platform, BullFrog AI has established licensing agreements with academic institutions, including George Washington University and Johns Hopkins University, to develop treatments for various diseases. These agreements grant BullFrog AI the rights to explore and commercialize novel therapeutic approaches, such as siRNA targeting Beta2-spectrin for liver diseases and a formulation of Mebendazole for cancer treatment. BullFrog AI's strategy involves combining its AI/ML capabilities with promising therapeutic candidates to create innovative solutions for unmet medical needs, positioning itself at the intersection of technology and biopharmaceuticals.

BFRG的投资论点是什么？

BullFrog AI Holdings, Inc. presents a high-risk, high-reward investment opportunity in the AI-driven drug discovery space. The company's bfLEAP platform offers potential for accelerated drug development and personalized medicine applications. Licensing agreements with universities provide access to promising therapeutic candidates, addressing diseases with significant market potential. However, the company's small size, limited financial resources, and early stage of development pose substantial risks. With a market capitalization of $0.01 billion and negative profitability (P/E of -0.97 and Profit Margin of -5770.7%), the company's financial stability is a concern. The success of BullFrog AI hinges on the validation of its AI platform, successful clinical trials, and securing additional funding to support its operations. The company's high beta of 0.71 indicates higher volatility than the market.

BFRG在哪个行业运营？

BullFrog AI operates within the rapidly evolving healthcare information services industry, where AI and machine learning are increasingly being adopted to accelerate drug discovery, improve clinical trial outcomes, and personalize treatment approaches. The market for AI in healthcare is projected to reach billions of dollars in the coming years, driven by the growing volume of healthcare data and the increasing need for efficient and cost-effective solutions. BullFrog AI competes with other AI-driven drug discovery companies, as well as traditional pharmaceutical companies that are investing in AI capabilities. The company's success depends on its ability to differentiate its platform, secure partnerships, and demonstrate clinical efficacy.

Medical - Healthcare Information Services

Healthcare

BFRG有哪些增长机遇？

Expansion of bfLEAP Platform Applications: BullFrog AI can expand the applications of its bfLEAP platform beyond drug discovery to include diagnostics, personalized medicine, and patient stratification. The market for AI-powered diagnostics is projected to reach $3 billion by 2028, offering a significant growth opportunity for the company. Success hinges on demonstrating the platform's versatility and accuracy in diverse healthcare settings.
Strategic Partnerships with Pharmaceutical Companies: Collaborating with established pharmaceutical companies can provide BullFrog AI with access to funding, resources, and clinical trial expertise. The pharmaceutical industry is increasingly seeking partnerships with AI companies to enhance their drug development pipelines, creating a favorable environment for strategic alliances. These partnerships could accelerate the validation and commercialization of BullFrog AI's platform and therapeutic candidates.
Development of Proprietary Therapeutic Candidates: Advancing its licensed therapeutic candidates through clinical trials and securing regulatory approvals can create significant value for BullFrog AI. The market for liver disease treatments is substantial, with a growing prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Successful development of a novel therapy in this area could generate substantial revenue and establish BullFrog AI as a leader in the field.
Geographic Expansion into International Markets: Expanding its operations into international markets, such as Europe and Asia, can diversify BullFrog AI's revenue streams and access new patient populations. The global market for AI in healthcare is growing rapidly, with significant opportunities in emerging economies. Successful international expansion requires adapting the platform and business model to local regulatory requirements and healthcare systems.
Leveraging Real-World Data for Personalized Medicine: By integrating real-world data from electronic health records and other sources, BullFrog AI can enhance the predictive power of its platform and develop personalized treatment strategies. The market for personalized medicine is growing rapidly, driven by the increasing availability of genomic data and the desire for more targeted and effective therapies. Success depends on establishing secure data partnerships and demonstrating the clinical utility of personalized medicine approaches.

Market capitalization of $0.01 billion, reflecting its small size and early stage of development.
Negative P/E ratio of -0.97, indicating current lack of profitability.
Gross margin of 18.8%, suggesting potential for improvement as the company scales.
Profit margin of -5770.7%, highlighting significant losses and the need for improved financial performance.
Beta of 0.71, indicating lower volatility compared to the broader market.

BFRG提供哪些产品和服务？

Develops and offers the bfLEAP AI/ML platform for analyzing preclinical and clinical data.
Focuses on AI/ML-driven analysis of data sets in the medical and healthcare fields.
Seeks to accelerate drug discovery and development through AI.
Pursues licensing agreements for novel therapeutic approaches.
Aims to identify patterns and insights in healthcare data that traditional methods might miss.
Targets diseases such as hepatocellular carcinoma, obesity, and non-alcoholic fatty liver disease through its licensing agreements.

BFRG如何赚钱？

Generates revenue through licensing its bfLEAP platform to pharmaceutical and biotechnology companies.
Receives milestone payments and royalties from the commercialization of therapeutic candidates developed through its licensing agreements.
May pursue strategic partnerships with pharmaceutical companies to co-develop and commercialize its products.

Pharmaceutical companies seeking to accelerate drug discovery and development.
Biotechnology companies looking to improve clinical trial outcomes.
Academic institutions and research organizations interested in leveraging AI/ML for healthcare research.

Proprietary AI/ML platform (bfLEAP) with potential for superior data analysis and insights.
Licensing agreements with leading universities providing access to novel therapeutic candidates.
Expertise in applying AI/ML to complex healthcare data sets.
First-mover advantage in specific therapeutic areas.

什么因素可能推动BFRG股价上涨？

Upcoming: Publication of preclinical data demonstrating the efficacy of its therapeutic candidates.
Upcoming: Announcement of new partnerships with pharmaceutical companies or research institutions.
Ongoing: Advancement of its therapeutic candidates through clinical trials.
Ongoing: Expansion of the bfLEAP platform's capabilities and applications.

BFRG的主要风险是什么？

Potential: Failure to secure additional funding to support its operations.
Potential: Clinical trial failures or regulatory setbacks.
Potential: Competition from larger and more established AI companies.
Ongoing: Dependence on licensing agreements and partnerships.
Ongoing: Rapid technological advancements in AI/ML could render its platform obsolete.

BFRG的核心优势是什么？

Proprietary AI/ML platform (bfLEAP).
Licensing agreements with reputable universities.
Focus on high-growth areas of AI in healthcare.
Potential for accelerated drug discovery and development.

BFRG的劣势是什么？

Small size and limited financial resources.
Early stage of development with no approved products.
High dependence on licensing agreements and partnerships.
Negative profitability and significant losses.

BFRG有哪些机遇？

Expansion of bfLEAP platform applications.
Strategic partnerships with pharmaceutical companies.
Development of proprietary therapeutic candidates.
Geographic expansion into international markets.

BFRG面临哪些威胁？

Competition from larger and more established AI companies.
Regulatory hurdles and clinical trial risks.
Failure to secure additional funding.
Rapid technological advancements in AI/ML.

BFRG的竞争对手是谁？

Biofrontera Inc. — Focuses on dermatological products. — (BFRI)
BioRestorative Therapies, Inc. — Develops cell therapies for various conditions. — (BRTX)
Cocrystal Pharma, Inc. — Develops antiviral therapeutics. — (COCP)
Co-Diagnostics, Inc. — Specializes in molecular diagnostics. — (CODX)
Datawatch Corporation — Provides data intelligence solutions. — (DWTX)

Key Metrics

MoonshotScore: 54/100

Company Profile

CEO: Vininder Singh
Headquarters: Gaithersburg, US
Employees: 4
Founded: 2023

AI Insight

AI analysis pending for BFRG

常见问题

What does Bullfrog AI Holdings, Inc. Common Stock do?

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company, employing artificial intelligence and machine learning to analyze complex datasets within the healthcare sector. Its core product, the bfLEAP platform, is designed to accelerate drug discovery and development by identifying patterns in preclinical and clinical data. Additionally, the company secures licensing agreements with universities to explore and develop novel therapeutic candidates for diseases like cancer and liver disease, aiming to create innovative solutions for unmet medical needs.

What do analysts say about BFRG stock?

As of 2026-03-17, there is no readily available analyst coverage for Bullfrog AI Holdings, Inc. Common Stock (BFRG). Given its small market capitalization and early stage of development, the stock may not be widely followed by analysts. Investors should conduct their own due diligence and consider the company's financial condition, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include market capitalization, P/E ratio, and gross margin.

What are the main risks for BFRG?

Bullfrog AI Holdings, Inc. faces several significant risks, including its small size, limited financial resources, and early stage of development. The company's success depends on the validation of its AI platform, successful clinical trials, and securing additional funding. Clinical trial failures, regulatory setbacks, and competition from larger companies could negatively impact its prospects. Additionally, the company's dependence on licensing agreements and partnerships exposes it to risks associated with those relationships.